Presentation is loading. Please wait.

Presentation is loading. Please wait.

Incidence of (A) recurrent VTE and (B) major bleeding in select randomised clinical trials of LMWH for the treatment and secondary prevention of VTE in.

Published byLibuše Vaňková Modified over 6 years ago

Similar presentations

Presentation on theme: "Incidence of (A) recurrent VTE and (B) major bleeding in select randomised clinical trials of LMWH for the treatment and secondary prevention of VTE in."— Presentation transcript:

1 Incidence of (A) recurrent VTE and (B) major bleeding in select randomised clinical trials of LMWH for the treatment and secondary prevention of VTE in patients with cancer. Incidence of (A) recurrent VTE and (B) major bleeding in select randomised clinical trials of LMWH for the treatment and secondary prevention of VTE in patients with cancer. CANTHANOX, Secondary Prevention Trial of Venous Thromboembolism With Enxoaparin; CATCH, Comparison of Acute Treatments in Cancer Hemostasis; CLOT, Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer; LITE, Long-Term Innohep Treatment Evaluation; LMWH, low-molecular-weight heparin; ONCENOX, Oncology and Enoxaparin; VKA, vitamin K antagonist; VTE, venous thromboembolism. Cihan Ay et al. ESMO Open 2017;2:e000188 Copyright © European Society for Medical Oncology. All rights reserved.

Download ppt "Incidence of (A) recurrent VTE and (B) major bleeding in select randomised clinical trials of LMWH for the treatment and secondary prevention of VTE in."

Similar presentations

Cancer-Associated Thrombosis

Cancer-Associated Thrombosis
Oral Rivaroxaban for Symptomatic Venous Thrombroenbolism Group 9 611 - 10/06/11.

Oral Rivaroxaban for Symptomatic Venous Thrombroenbolism Group /06/11.
Assessment of the Effect of Target Specific Oral Anticoagulants for Treatment of Venous Thromboembolism in Oncology Patients Good morning. My name is.

Assessment of the Effect of Target Specific Oral Anticoagulants for Treatment of Venous Thromboembolism in Oncology Patients Good morning. My name is.
Clinical Professor in Palliative Medicine

Clinical Professor in Palliative Medicine
The efficacy and safety of oral Rivaroxaban in patients with permanent inferior vena cava filter: a pilot case-control study Lobastov K., Barinov V.,

The efficacy and safety of oral Rivaroxaban in patients with permanent inferior vena cava filter: a pilot case-control study Lobastov K., Barinov V.,
Volume 130, Issue 6, Pages (December 2006)

Volume 130, Issue 6, Pages (December 2006)
Copyright © 2003 American Medical Association. All rights reserved.

Copyright © 2003 American Medical Association. All rights reserved.
APEX Trial design: Patients hospitalized with an acute medical illness were randomized to oral betrixaban for 35-42 days (n = 3,759) versus subcutaneous.

APEX Trial design: Patients hospitalized with an acute medical illness were randomized to oral betrixaban for days (n = 3,759) versus subcutaneous.
Copyright © 2000 American Medical Association. All rights reserved.

Copyright © 2000 American Medical Association. All rights reserved.
Long-term Low-Molecular-Weight Heparin versus Usual Care in Proximal-Vein Thrombosis Patients with Cancer  Russell D. Hull, MBBS, MSc, Graham F. Pineo,

Long-term Low-Molecular-Weight Heparin versus Usual Care in Proximal-Vein Thrombosis Patients with Cancer  Russell D. Hull, MBBS, MSc, Graham F. Pineo,
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis by Paolo Prandoni,

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis by Paolo Prandoni,
Thrombosis, Cancer, and NOACs

Thrombosis, Cancer, and NOACs
Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.

Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.
The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.

The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.
Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.

Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart summarising the process for the identification of eligible studies.

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart summarising the process for the identification of eligible studies.
New Oral Anticoagulants and VTE Management

New Oral Anticoagulants and VTE Management
A Better Solution For Cancer Patients With VTE?

A Better Solution For Cancer Patients With VTE?
VTE in Cancer.

VTE in Cancer.
Forest plot of the HRs for DOACs vs warfarin for (A) new or recurrent VTE and (B) major bleeding based on the published subanalyses of the patients with.

Forest plot of the HRs for DOACs vs warfarin for (A) new or recurrent VTE and (B) major bleeding based on the published subanalyses of the patients with.

Similar presentations

Ads by Google